97 results about "Serum protein" patented technology

The invention discloses a biomarker combination related to hypoxia-induced neuroinflammation and application of the biomarker combination, and belongs to the technical field of biomarker detection. The marker combination disclosed by the invention consists of serum S100 beta protein, neuron-specific enolase, interleukin-6, high-mobility group protein B1 and neurofilament light-chain protein. The marker combination can be used for stratification of nervous system injury risk of severe hypoxia patients and acquisition of prognosis evaluation data. According to the detection method disclosed by the invention, synchronous quantitative detection of five markers is realized by adopting a multiple immunofluorescent microsphere technology, and a marker combination scoring algorithm is established to comprehensively evaluate the severity of the hypoxia-related neuroinflammation.

The invention belongs to the technical field of in-vitro diagnosis and anesthesia monitoring. The invention discloses a serum protein marker combination for evaluating anesthesia depth and application of the serum protein marker combination. The composition is composed of orexin, S100 calcium binding protein B, C reactive protein and gamma-aminobutyric acid A type receptor alpha1 subunit, and can synergistically reflect the anesthesia sedation state from multiple dimensions. The invention also provides a detection kit containing the marker and application of the detection kit in evaluation of anesthesia depth. The combination has the advantages of being high in accuracy, objective, stable and easy to detect, can serve as an effective supplementary tool of an existing nerve electrophysiology monitoring technology, and provides a new reference means for intraoperative sedation depth monitoring and precise anesthesia management.

The application discloses a preparation method and application of a polyacid tannic acid modified ultrafiltration membrane, and the preparation method comprises the following steps: preparing a casting solution containing a high molecular film forming material and a solvent; adding a polyoxometalate into the casting solution, uniformly mixing, and obtaining a polyacid modified casting solution; scraping and coating the polyacid modified casting solution to form a liquid membrane, pre-evaporating, immersing into a coagulation bath containing tannic acid to perform phase inversion and film forming, and obtaining the polyacid tannic acid modified ultrafiltration membrane. Through the synergistic effect of the polyacid blending regulation of the membrane pore structure and the in-situ coordination modification of the tannic acid phase separation, the simultaneous improvement of the permeation flux and the retention rate is realized, the pure water flux of the obtained ultrafiltration membrane reaches 221.37 LMH, the bovine serum albumin retention rate reaches 96.17%, and the preparation process is simple, efficient, and has a good large-scale application prospect.

The application discloses a micro serum tumor whole-process screening detection method based on nucleic acid aptamer group comparison, and comprises the following steps: firstly, 24+1 tumor and non-tumor specific nucleic acid aptamer groups are screened by using bidirectional thermal cycle subtraction SELEX technology; data of the specific nucleic acid aptamer groups are used to create a standard database; the specific nucleic acid aptamer groups are mixed in equal proportions to develop 24+1 tumor and non-tumor specific nucleic acid aptamer detection reagents; in the detection process, the detected sample forms a magnetic bead-sample serum protein complex, and then is combined with the aptamer detection reagent; a magnetic bead-serum protein-sample specific nucleic acid aptamer complex is formed, and sample specific nucleic acid aptamer is separated and obtained; and the sample specific nucleic acid aptamer is compared and analyzed with the standard database, so that the sample detection technology method is realized. The method has the advantages of small sample amount, automatic process completion, high throughput, wide tumor screening range and the like, and meets the requirements of high-throughput tumor screening.

The application belongs to the field of biotechnology, and particularly relates to application of UBQLN1 protein in a cirrhosis diagnosis product, a kit and an in vitro detection method. The application comprises: using serum UBQLN1 protein as a marker, and applying the marker in preparation of a product for diagnosing or assisting in diagnosing cirrhosis; or applying the marker in preparation of a product for distinguishing cirrhosis from healthy individuals; or applying the marker in preparation of a product for evaluating progression of cirrhosis or a degree of liver fibrosis; and applying the marker in screening or evaluating a drug for preventing and / or treating cirrhosis.

The invention provides a biomarker for diagnosing primary biliary cholangitis and application of the biomarker, and belongs to the technical field of biomarkers. The biomarker disclosed by the invention comprises serum protein and / or N-glycopeptide. According to the method, the improvement of PBC diagnosis is taken as a starting point, the serum protein and the N-glycopeptide are taken as screening templates, a more accurate non-invasive prediction means for differential diagnosis of PBC is provided, and a theoretical basis is provided for rapid and accurate diagnosis of PBC.

The utility model relates to the technical field of cosmetic packaging, in particular to a serum protein active water film vacuum fresh-keeping glass bottle packaging device. The device comprises a storage assembly and a pumping assembly, the pumping assembly is connected with the storage assembly and extracts objects stored in the storage assembly outwards, the pumping assembly is externally connected with a smearing assembly, sealing assemblies are installed on the storage assembly and the smearing assembly, and the sealing assemblies control opening and closing installation. The storage assembly is designed to be in vacuum sealing, contact between oxygen in air and a serum protein active water film is remarkably reduced, the oxidation risk is reduced, the shelf life of the product is prolonged, the pumping assembly can accurately control the dosage extracted each time, waste is avoided, meanwhile, it is ensured that the dosage used each time is consistent, and the service life of the product is prolonged. The pumping mechanism reduces the opportunity that fingers of a user make direct contact with the product, pollution risks are reduced, product sanitation is guaranteed, the external smearing assembly is designed to be suitable for direct use, intermediate operation steps are reduced, and the user can smear the product easily.

The invention discloses a method for analyzing serum differential expression protein characteristics of an AQP4-IgG positive NMOSD patient, and relates to the technical field of differential expression protein characteristic analysis, and the method comprises the following steps: S1, collecting a serum sample of a to-be-detected subject; s2, carrying out protein detection on the serum sample to obtain expression level data of at least one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8, wherein the expression level data is one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8; s3, carrying out comparative analysis on the expression level of the serum protein and a pre-established AQP4-IgG positive NMOSD serum protein expression characteristic reference standard; according to the method for auxiliary diagnosis of the AQP4-IgG positive neuromyelitis optica pedigree disease provided by the invention, a judgment mode capable of reflecting molecular characteristics of the AQP4-IgG positive neuromyelitis optica pedigree disease is constructed by carrying out conjoint analysis on various serum protein expression characteristics related to immunoregulation, inflammatory response, complement activation and metabolism; therefore, the problem of insufficient detection stability of a single biomarker is avoided.

This invention provides a serum protein biomarker for early screening and diagnosis of pancreatic ductal adenocarcinoma. The serum protein biomarker is one or a combination of two or more autoantibodies against tumor-associated antigens HEXB, TXLNA, and SLAMF6. The invention also provides the application of reagents, kits, and analytical methods for detecting the serum protein biomarker. This invention screens for autoantibodies against pancreatic ductal adenocarcinoma-associated antigens. By measuring the expression levels of these indicators in the serum of patients with pancreatic ductal adenocarcinoma, healthy controls, and controls with benign pancreatic diseases, the screened anti-HEXB, anti-TXLNA, and anti-SLAMF6 autoantibodies can distinguish between pancreatic ductal adenocarcinoma, healthy controls, and benign pancreatic diseases. Furthermore, this invention designs and optimizes combinations of tumor-associated antigens for the diagnosis of pancreatic ductal adenocarcinoma. Applying the optimized antigens to an ELISA kit and detecting serum anti-TAA autoantibodies using an indirect enzyme-linked immunosorbent assay (ELISA) can accurately identify patients with pancreatic ductal adenocarcinoma, healthy controls, and patients with benign pancreatic diseases.

The invention discloses a serum protein marker combination for detecting cerebral microhemorrhage, and belongs to the field of biological medicine detection.The serum protein marker combination comprises four serum proteins including matrix metalloproteinase 3, fibronectin-like extracellular matrix protein 1 containing epidermal growth factors, a metalloproteinase inhibiting factor 1 and uromodulin; through efficient and accurate serum protein marker combination, the defects that brain function magnetic resonance SWI examination is high in cost and long in time consumption, operation depends on high-level imaging physicians and the like are overcome, an innovative tool is provided for rapid, accurate and non-invasive screening and auxiliary diagnosis of cerebral microhemorrhage, and wide clinical application prospects are achieved.

This invention relates to a method for producing serum protein concentrate, wherein at least one of the microbial reduction steps includes treatment with UV-C radiation, thereby increasing the content of heat-sensitive bioactive components and improving the sustainability of the serum protein concentrate production method.

The application belongs to the technical field of membrane separation, and particularly relates to a small-aperture high-flux ultrafiltration membrane and a preparation method and application thereof. Polymer material, an additive and an organic solvent are mixed, constant-temperature stirring and standing defoaming are performed to obtain a casting solution, and then a non-solvent phase separation method is used to prepare the ultrafiltration membrane. The polymer material comprises polyethersulfone and sulfonated polyphenylsulfone with a mass ratio of 95:5-80:20, and the additive is polyethylene glycol. The rejection rate of the ultrafiltration membrane to bovine serum albumin (BSA) is above 99%, the rejection rate of direct red 23 and coomassie brilliant blue and other dyes can be above 96%, and the pure water permeability is 310 L·m ‑2 ·h ‑1 ·bar ‑1 , which has a wide application prospect in the fields of antibody protein purification and concentration, dye desalination and nanoscale pollutant treatment in wastewater.

The anti-cancer use of a camptothecin derivative which demonstrates a surprising resistance to the degrading effects of Human Serum Albumin ("HSA") in vivo is disclosed. Since HSA represents about half of serum protein in human blood, previous camptothecins generally worked poorly or not at all in vivo due to inactivation by HSA among other factors. Since NSS-01 is similar in mechanism of action to other camptothecins, and as demonstrated herein has both: (i) greater anti-tumor activity against various human cancers and (ii) less toxicity at therapeutic dosing - than topotecan and irinotecan; and without wishing to be bound by theory, NSS-01 demonstrated desirable antitumor activity against adenocarcinomas, it therefore should demonstrate desirable antitumor activity against other cancers that are susceptible to Topoisomerase I inhibitors.

The invention belongs to the technical field of medical detection and biological medicine, and discloses a serum protein marker combination for glioma diagnosis and prognosis evaluation and a processing system of the serum protein marker combination. Eight algorithms including KNN, SVM, random forest, XGBoost, AdaBoost, LGBM, Gaussian naive Bayes and decision tree cover traditional machine learning and integrated learning, and model robustness is improved; according to the method, interpretable feature screening is adopted, SHAP and LIME tools are combined, the contribution degree of each marker to a diagnosis result is clarified, and the problem of'black box 'of machine learning is solved; the invention provides a machine learning algorithm-based mass spectrometry system for glioma detection, which is good in detection performance, high in speed, convenient to operate and low in cost, so as to meet the requirements of clinical early diagnosis and non-invasive examination of glioma.

The invention discloses an application of a serum protein biomarker in preparation of an auxiliary evaluation reagent related to feline calicivirus infection. The biomarker is long-chain acyl coenzyme A synthetase 4 (ACSL4) or calcium binding protein S100A2. When the expression level of the ACSL4 protein in the serum of the to-be-detected cat is obviously increased relative to the expression level in the control serum of a healthy cat, the FCV infection induced lung injury is indicated; when the expression level of the S100A2 protein in the serum of the to-be-detected cat is obviously reduced relative to the expression level in the control serum of the healthy cat, the FCV infection related oral lesion prognosis is poor. The serum ACSL4 and S100A2 can be used as specific biomarkers of FCV infection, so that the problem of high detection false negative rate caused by high virus variation is solved, the diagnosis accuracy is remarkably improved, and quantitative evaluation on clinical prognosis of FCV infection is realized.

This invention relates to the field of biotechnology, and more particularly to a biomarker, kit, and application for the diagnosis of pancreatic malignant tumors. The biomarker comprises aldehyde-ketone reductase 1B10 protein and carbohydrate antigen 19-9 protein. This biomarker is a secreted serum protein that can specifically distinguish PDAC patients from normal individuals, and from individuals with benign pancreatic diseases, exhibiting high specificity without significant non-specific elevation interference. Combined detection with CA199 can synergistically enhance diagnostic efficacy, significantly reducing the rate of missed diagnoses and misdiagnoses. Simultaneously, this biomarker can assess the postoperative tumor resection effect in PDAC patients, predict whether curative resection is achieved, and provide an effective target for postoperative prognostic monitoring.

The invention belongs to the technical field of biological detection, and discloses a kit for detecting the concentration of human serum C4BP-a and a use method. The kit comprises an antibody for detecting human serum C4BP-a protein, deionized water PBS, a 96-well plate, a well plate covering film, a standard substance, a C4BP-a standard substance diluent, a detection solution A, a detection diluent A, a detection solution B, a detection diluent B, a TMB substrate solution, a stop solution and a concentrated washing solution. The invention provides a brand new marker human serum C4BP-a protein for predicting clopidogrel resistance, and the marker as a detection target can predict or assist in judging the clinical curative effect or prognosis of a patient after taking medicine.

The invention provides a transdermal absorption composition containing six active peptides and application of the transdermal absorption composition. The transdermal absorption composition is prepared from 0.5 to 5 parts of acetyl hexapeptide-8, 0.5 to 5 parts of decapeptide-4, 0.5 to 5 parts of oligopeptide-1, 1 to 10 parts of glycoprotein, 1 to 8 parts of serum protein, 5 to 20 parts of soluble collagen, 3 to 12 parts of mannitol, 2 to 10 parts of trehalose, 1 to 5 parts of caprylyl glycol and 5 to 25 parts of butanediol. The composition is used for preparing transdermal absorption products for improving ovarian functions and delaying ovarian aging. Through a penetration enhancer combination and raw material modification process, the technical problems that polypeptide is difficult to transdermal and easy to inactivate are effectively solved, and the skin permeability and stability of active ingredients are improved, so that the ovarian function is improved through synergistic interaction.

The invention discloses application of serum alpha-non-red blood cell ghost protein 1 in preparation of drugs for diagnosing heart light chain amyloidosis diseases, and belongs to the technical field of biological medicines. The serum SPTAN1 protein is used for preparing the medicine for diagnosing the heart light-chain amyloidosis disease, the medicine is limited to be an enzyme linked immunosorbent assay kit, and the kit comprises an antibody of the SPTAN1 protein and further comprises a pre-coated plate, a standard substance, a coating buffer solution, a sample diluent, a confining liquid, horse radish peroxidase, an eluent and a color developing agent. The concentration of the SPTAN1 protein in the serum is measured through an enzyme linked immunosorbent assay kit, and early diagnosis of the heart AL amyloidosis disease is carried out. The invention provides a novel, efficient and sensitive biomarker, namely the serum SPTAN1 protein, early diagnosis of heart AL amyloidosis is realized by detecting the concentration of the SPTAN1 protein in serum, and the serum SPTAN1 protein has an important clinical application prospect.

This invention discloses a composite anticoagulant coating, its preparation method, and its applications, belonging to the field of biomedical technology. This invention provides a novel composite anticoagulant coating. Through the following innovative design: using multi-thiol proteins (bovine serum albumin, lysozyme, etc.) as coating substrates, in-situ bio-orthogonal multiple grafting is performed on their thiol groups and amino groups to achieve multifunctionality of anticoagulation, anti-inflammation, and antibacterial properties; through the amyloid aggregation of proteins, a strong target substrate is formed and anchored, resisting blood flow impact and improving coating stability. This invention, through bio-orthogonal design, modifies the thiol groups and amino groups of the coating proteins separately to achieve non-conflicting multifunctionality. Specifically, by modifying the disulfide bonds (-S-S-) and branched amino groups (-NH2) of the proteins, dual active sites of -SH and -GA are constructed for grafting modification, allowing the grafted substances to achieve their multifunctionality of anticoagulation, anti-inflammation, and antibacterial properties without interference.

The invention relates to the technical field of biology, in particular to a preserving fluid for preserving in-vitro fresh tissues and single cell activity and a preparation method thereof. The preserving fluid can preserve in-vitro fresh tissues and single cell activity at the low temperature of 4 DEG C, and comprises the following components: D-glucose, sodium chloride, potassium chloride, magnesium chloride, sodium dihydrogen phosphate, L-glutamine, L-histidine, L-phenylalanine, L-methionine, L-cysteine, L-glutamic acid, L-tryptophan, L-arginine, L-serine and L-alanine. The feed additive is prepared from L-propylamine-glutamine, vitamin E, vitamin C and bovine serum albumin. The tissue and cell viability preservation reagent has the following technical effects that the tissue and cell viability preservation reagent provided by the invention can stably preserve in-vitro fresh tissues under the condition of 4 DEG C, the viability of a single cell is at least 85% or above within 72 hours, and the tissue and cell viability preservation reagent is suitable for transportation and detection of third-party detection institutions and hospital samples; and a technical support is provided for a single cell sequencing experiment with a high motility rate requirement.

The utility model provides a suspension cell culture and drug concentration generation integrated micro-fluidic chip, which structurally comprises culture units which are stacked in series, a liquid inlet and a liquid outlet which are mutually independent, each unit comprises a matrix, each culture layer is provided with an independent culture channel, and the micro-channel is modified by bovine serum albumin molecules. A closed loop is formed by vertical overlapping, and cell implantation is realized by a laminar flow phenomenon. And meanwhile, two driving channels are crossed with the culture channel and are separated from the culture channel by an elastic diaphragm. Two ends of the driving channel are communicated with the outside. The liquid inlet and the liquid outlet which are independent from each other automatically form a medicament with a gradient medicament concentration from the sample liquid inlet, the influence of the change of the concentration of the medicament on blood cell culture is researched, the chip suspension culture simulates the real environment of lung cells in vivo, and the bovine serum albumin molecule modification simplifies the cell implantation process. Medicaments with different concentrations are added into different channels, and the optimal concentration range is determined by observing the influence of the medicaments. The method has the advantages of high efficiency and economy.

The invention provides a biomarker for predicting the prognosis effect of ursodesoxycholic acid for primary biliary cholangitis and application of the biomarker, and belongs to the technical field of biomarkers. The biomarker disclosed by the invention comprises an activating agent AHSA1 of a 90 kDa heat shock protein ATPase homolog 1 and a glycosylated form C4BN226HexNAc (2) Hex( 7) of a complement C4-B. The invention further discloses a preparation method of the biomarker. According to the method, the improvement of the PBC medication efficiency is taken as a starting point, the serum protein and the N-glycopeptide are taken as screening templates, a more accurate non-invasive prediction means for the curative effect of the PBC medication UDCA is provided, and a theoretical basis is provided for personalized treatment of PBC.

This invention provides a cosmetic composition with anti-wrinkle and repairing effects, its preparation method, and its application. The cosmetic composition with anti-wrinkle and repairing effects includes polydeoxyribonucleotides, fibronectin, and serum proteins. In the composition of this invention, polydeoxyribonucleotides can rapidly activate cell activity, while fibronectin and serum proteins, as core nutrients, can quickly enter the skin using the already repaired skin's metabolic capacity. The combination of these three components has a synergistic effect, which can significantly improve the skin's wrinkle-reducing and repairing effects.

The application provides a serum proteomics and machine learning-based Kawasaki disease intravenous immunoglobulin (IVIG) resistance biomarker combination and screening method, and belongs to the technical field of medicines. The method comprises the following steps: (1) on the basis of establishing strict inclusion criteria and typing criteria, collecting whole blood samples of IVIG reaction type and non-reaction type Kawasaki disease children before treatment; (2) using DIA proteomics technology for systematic screening and differential protein identification; (3) weighted co-expression network analysis, screening of protein modules significantly related to IVIG non-reaction phenotype; (4) combined with LASSO-Logistic regression and SVM-RFE for multi-step feature screening, identifying five biological markers significantly related to IVIG resistance: PLA2G4A, SNX17, PURB, CERS3 and CASP1 (5) based on the marker expression level, using the pROC package for ROC analysis and calculating AUC; (6) analyzing the correlation between the marker and the clinical index related to Kawasaki disease; (7) after limma processing in the independent transcriptome set GSE18606, using glm to construct a multivariate binary logistic regression prediction model and perform ROC analysis. Through independent transcriptome dataset verification, the biomarker combination screened by the application can realize effective prediction of Kawasaki disease IVIG resistance, and shows good prediction performance and clinical application value.

The application discloses a solution for separating fat cell nucleus and cytoplasm, and the solution comprises solution 1 and solution 2; wherein the solution 1 comprises 8-12 mM hydrochloride buffer, 0.03-0.15% Tween-20, 8-12 mM sodium chloride, 2-4 mM magnesium chloride, 0.8-2% bovine serum albumin and 0.4-0.6% ethyl phenyl polyethylene glycol; the solution 2 comprises 8-12 mM hydrochloride buffer, 8-25 mM sodium chloride, 1-15 mM magnesium chloride and 0.8-2.5% bovine serum albumin; the percentage is volume percentage. The application can realize the research on all cell types of fat tissues, greatly reduces the required amount of fat tissues and improves the possibility of carrying out single cell research. The application can be used for both transcriptome research and epigenetic research.

The invention discloses a snake wound classification and recognition model construction method based on serum marker electrochemical detection and deep learning, and belongs to the technical field of biosensing and intelligent diagnosis. The method comprises the following steps: firstly, screening based on proteomics to obtain multiple serum protein biomarkers related to snake bite types, constructing a multi-electrode electrochemical sensing platform, and collecting electrochemical signals through cyclic voltammetry (CV) to obtain electrochemical fingerprint characteristics of a serum sample; and after the obtained signal is subjected to normalization and data enhancement processing, the signal is input into a one-dimensional convolutional neural network (1D-CNN) model for feature learning and classification identification. Through combination of multi-index detection of biomarkers and an end-to-end deep learning algorithm, the method realizes rapid and accurate identification of three different snake wound types of agkistrodon acutus, cobra and trimeresurus remeresurus. The invention constructs a high-sensitivity and rapid diagnosis method for snake wounds, and the method has good popularization and clinical transformation potential.

This invention provides a class of near-infrared molecular probes that specifically bind to human serum albumin, their preparation methods, and applications. The near-infrared molecular probes are one of NFH-1, NFH-2, NFH-3, NFH-4, NFH-5, NFH-6, and NFH-7, with the general formula: [Formula omitted for brevity]. In this formula, R is selected from methyl, benzyl, fluorobenzyl, phenethyl, 2,4-dimethylbenzyl, 3-methoxybenzyl, and p-carboxybenzyl. This invention uses a hydroxyl hemicyanine dye as the fluorophore and introduces a series of hydrophobic functional groups (-R) onto the phenolic hydroxyl group to regulate molecular properties to match the hydrophobic domains of human serum albumin. These probes can avoid background interference from endogenous substances in clinical blood samples, improve the signal-to-noise ratio and accuracy of detection, and are simple to prepare, fluorescently sensitive, highly resistant to interference, and highly stable, providing an efficient tool for clinical human serum albumin detection.

The invention discloses a novel immunosensor capable of realizing trace detection of A beta oligomer as well as a preparation method and application of the immunosensor. The preparation method of the immunosensor comprises the following steps: forming a gold nanoparticle-reduced graphene oxide composite layer; the gold nanoparticle-reduced graphene oxide composite layer is covered with cobalt-molybdenum disulfide composite suspension liquid to form a cobalt-molybdenum disulfide composite layer; covering the cobalt-molybdenum disulfide complex layer with an anti-A beta oligomer antibody solution to obtain an anti-A beta oligomer antibody layer; and covering bovine serum albumin on the anti-A beta oligomer antibody layer, and incubating for 30-60 minutes to obtain the immunosensor. According to test determination, the linear range of the immunosensor constructed by the invention is 1.11 * 10 <-9 > M to 1.11 * 10 <-14 > M, and the detection limit can be as low as 6.87 * 10 <-15 > M.

The application provides a kit for detecting sialylated carbohydrate antigen KL-6 and a use method and application thereof, and relates to the field of in vitro detection. The kit for detecting sialylated carbohydrate antigen KL-6 provided by the application comprises magnetic beads, KL-6 antibodies, acridinium ester, a magnetic bead storage solution, an acridinium ester storage solution, a sample processing solution, a pre-priming solution and a priming solution. The sample processing solution comprises, in terms of mass fraction, 0.03-0.3% polyoxyethylene fatty acid ester, 0.3-2.0% bovine serum albumin, 0.3-2.0% raffinose, 0.3%-2.0% sodium hydroxide, 0.01-1.5% NaN3 and 0.3-1.5% sodium chloride, the rest is purified water, and the pH is 8-10. The kit can be used for determining sialylated carbohydrate antigen KL-6 in serum, and has high accuracy and strong anti-interference ability.